Evinacumab (Evkeeza, Ultragenyx) is indicated 'as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL‑C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH)'.
The dosage schedule is available in the summary of product characteristics for evinacumab.
The list price of evinacumab is £6,433 per 345‑mg vial for injection (excluding VAT; BNF online, accessed July 2024).
The company has a commercial arrangement. This makes evinacumab available to the NHS with a discount. The size of the discount is commercial in confidence.